IL-17拮抗剂治疗斑块状银屑病的疗效与安全性荟萃分析
该荟萃分析检索截至2016年5月的随机对照试验,纳入9项RCT共5951例患者,评估IL-17拮抗剂治疗斑块状银屑病的疗效与安全性。结果显示其PASI 75/90/100及IGA 0/1应答率高于安慰剂,但任何不良事件和感染比例更高,严重不良事件与心血管事件未见显著差异。
要点
- IL-17拮抗剂PASI 75/90/100应答率优于安慰剂
- 任何不良事件及感染发生率高于安慰剂
- 严重不良事件与心血管事件与安慰剂无显著差异
核心结论
- IL-17拮抗剂对斑块状银屑病有效且安全性可接受,但需警惕感染风险。
研究设计与样本
- 荟萃分析,检索截至2016年5月发表的随机对照试验,最终纳入9项RCT、5951例患者,使用Review Manager 5.2软件分析。
主要发现
- IL-17拮抗剂的PASI 75、90、100应答率及DLQI 0/1应答率均高于安慰剂,因疗效不足停药的比例更低。
- 严重不良事件、心血管疾病及因不良事件停药的比例与安慰剂无显著差异。
- 任何不良事件和感染的患者比例高于安慰剂。
关键数值与推荐
- 疗效指标包括PASI 75/90/100应答、IGA 0/1应答;安全性指标包括不良事件、严重不良事件、心血管疾病、感染及停药。
临床怎么用
- 可用于斑块状银屑病治疗选择参考,使用中应监测感染相关风险。
局限性
- 检索截止2016年5月,纳入研究数量有限(9项RCT)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The interleukin-17 (IL-17) cytokine pathway plays a key role in the development of psoriasis. Antibodies targeting IL-17 or blocking its receptor may be a new therapeutic approach for psoriasis. To assist treatment selection in daily practice, it is essential to understand the benefit and risk profile of IL-17 antagonists. OBJECTIVE: We performed a meta-analysis to evaluate the efficacy and safety of IL-17 antagonists in patients with psoriasis. METHODS: We searched a number of databases for relevant randomized controlled trials (RCTs) published before May 2016. The following outcomes were evaluated: Psoriasis Area and Severity Index (PASI) 75, 90, 100 response, Investigator's Global Assessment (IGA) score of 0 or 1 response, adverse events (AEs) and withdrawals. The meta-analysis was performed using Review Manager 5.2 software. RESULTS: Nine RCTs with 5951 patients were included. IL-17 antagonists achieved higher PASI 75, 90, 100 response rates and Dermatology Life Quality Index 0 or 1 response rates than placebo and a lower incidence of discontinuations due to lack of efficacy. In the safety analysis, no significant differences were found between the IL-17 antagonists and placebo in the proportion of patients with serious AEs, cardiovascular disease and discontinuations due to AEs. However, IL-17 antagonists were associated with a higher proportion of patients with any AEs and infections than placebo. CONCLUSION: IL-17 antagonists were effective, with an acceptable safety profile, for patients with plaque psoriasis. Vigilance because of the potential for infection will be necessary for IL-17 antagonists.
引用
- Wu D, Hou SY, Zhao S, et al. Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2017. PMID: 28107570. doi:10.1111/jdv.14125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。